Literature DB >> 6292092

Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

J T Rector, R N Lausch, J E Oakes.   

Abstract

Monoclonal antibodies specific for the five major glycoproteins of herpes simplex virus type 1 (HSV-1) were tested for their capacity to mediate immunity to ocular HSV-1 infection. The specificity of the immunoglobulin made by each monoclone was determined by immunoprecipitation of [14C]glucosamine-labeled polypeptides from detergent-solubilized HSV-1-infected cells. Of the five monoclonal antibodies studied, two immunoprecipitated glycoproteins gA/B, one immunoprecipitated glycoprotein gC, one immunoprecipitated glycoprotein gD, and one immunoprecipitated glycoprotein gE. All five were effective in passively transferring immunity to mice when they were given 4 to 24 h after HSV-1 infection on an abraded cornea. Four of the monoclonal antibodies were also evaluated for their capacity to neutralize HSV-1 and to promote complement-mediated cell lysis and antibody-dependent cellular cytotoxicity. It was found that none of these in vitro assays correlated with the protective activity of the antibodies in vivo. In fact, one of the monoclonal antibodies was unreactive in all three immunological reactions, even though it was highly effective in promoting recovery from HSV-1 induced ocular disease in vivo. The results suggest that antibodies can interact in vivo with virus-specific glycoproteins gA/B, gC, gD, and gE to initiate recovery from HSV-1-induced ocular disease, and that the therapeutic effectiveness of a specific monoclonal antibody does not correlate with its immunological reactivity in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292092      PMCID: PMC347713          DOI: 10.1128/iai.38.1.168-174.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity.

Authors:  M Sarmiento; M Haffey; P G Spear
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

2.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

3.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

4.  Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation.

Authors:  F B Knotts; M L Cook; J G Stevens
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

5.  Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus.

Authors:  S L Shore; A J Nahmias; S E Starr; P A Wood; D E McFarlin
Journal:  Nature       Date:  1974-09-27       Impact factor: 49.962

6.  Inhibition or enhancement of immunological injury of virus-infected cells.

Authors:  A M Brier; C Wohlenberg; J Rosenthal; M Mage; A L Notkins
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

7.  Inability of antiserum active in antibody-dependent cellular cytotoxicity and arming tests to protect against simian virus 40 tumor cell challenge.

Authors:  S O Prather; R W Geller; R N Lausch
Journal:  J Natl Cancer Inst       Date:  1979-05       Impact factor: 13.506

8.  Murine antibody-dependent cellular cytotoxicity to herpes simplex virus-infected target cells.

Authors:  S Kohl; D L Cahall; D L Walters; V E Schaffner
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

9.  Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.

Authors:  H S Shin; M Hayden; S Langley; N Kaliss; M R Smith
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

10.  Type-common CP-1 antigen of herpes simplex virus is associated with a 59,000-molecular-weight envelope glycoprotein.

Authors:  G H Cohen; M Katze; C Hydrean-Stern; R J Eisenberg
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

View more
  40 in total

1.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

3.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.

Authors:  P A Offit; R D Shaw; H B Greenberg
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

4.  Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins.

Authors:  M Ito; T Ihara; C Grose; S Starr
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

5.  Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions.

Authors:  M F Para; M L Parish; A G Noble; P G Spear
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

6.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

7.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

8.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

9.  Glycoprotein B switches conformation during murid herpesvirus 4 entry.

Authors:  Laurent Gillet; Susanna Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

10.  Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.

Authors:  H F Staats; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.